The partnership will combine DoMore’s CE-IVDD marked Histotype Px Colorectal digital biomarker with Proscia’s CE-IVDR marked Concentriq Dx enterprise pathology platform, to provide new insights that can guide precise treatment decisions
DoMore partners with Proscia. (Credit: Trnava University on Unsplash)
Norway-based precision diagnostics company DoMore Diagnostics has partnered with US-based digital pathology solutions provider Proscia to help predict outcomes for colorectal cancer (CRC) patients.
The partnership integrates AI-powered clinical decision support into routine pathology workflows, providing new insights that can guide precise treatment decisions.
It will combine DoMore’s CE-IVDD marked Histotype Px Colorectal digital biomarker with Proscia’s CE-IVDR marked Concentriq Dx enterprise pathology platform.
DoMore Diagnostics CEO and co-founder Torbjørn Furuseth said: “We have proven that Histotype Px Colorectal can offer valuable insight to guide personalized treatment decisions and help improve patient outcomes.
“We must now continue to integrate the algorithm into pathologists’ routine operations for it to make the greatest impact. As leading laboratories are increasingly turning to Proscia, our partnership paves the way for accelerating its adoption.”
Concentriq Dx is an enterprise pathology platform that drives primary diagnostic workflows for reference laboratories, hospitals, and health systems of all sizes.
It enables pathologists to rapidly shift from the microscope and work with speed and ease.
According to the data from previously published studies, the Histotype Px Colorectal test can predict outcomes for patients with stage 2 and stage 3 CRC.
The test provides tumour and lymph node status, along with information about patients’ risk profile and 5-year cancer-specific survival to inform the decision to use adjuvant chemotherapy.
Concentriq Dx integrates AI applications from Proscia, its customers and third parties, including DoMore Diagnostics, into routine workflows.
Proscia strategic alliances head Stephan Fromme said: “Laboratories are increasingly demanding an open approach to digital pathology. They recognize that unlocking more utility for pathologists and patients means tapping into the collective power of a growing number of solutions.
“We look forward to adding Histotype Px Colorectal to our ecosystem to help our users make increasingly personalized diagnoses that can ultimately reduce overtreatment for more patients.”